The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Active surveillance in metastatic renal cell carcinoma: A single-center cohort.
 
William Schwartzman
Stock and Other Ownership Interests - Johnson & Johnson
 
Roy Elias
No Relationships to Disclose
 
Malvika Govil
No Relationships to Disclose
 
Waseem Nosair
No Relationships to Disclose
 
Alana Christie
No Relationships to Disclose
 
Kevin Dale Courtney
Stock and Other Ownership Interests - Regeneron (I)
Consulting or Advisory Role - Exelixis
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma; Astellas Pharma (Inst); Astellas Pharma (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Proacta (Inst); Stemline Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I)
 
Isaac Alex Bowman
Consulting or Advisory Role - Dendreon; Foundation Medicine
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck Sharp & Dohme (Inst)
 
Waddah Arafat
Stock and Other Ownership Interests - Myovant Sciences
Consulting or Advisory Role - Seagen
Research Funding - Merck (Inst); Seattle Genetics/Astellas (Inst)
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
James Brugarolas
Consulting or Advisory Role - Arrowhead Pharmaceuticals; Calithera Biosciences; Dartmouth College; Eisai; Exelixis; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Patent of HIF-2 biomarker; Patent pertaining HIF2a resistance mutations; U.S. patent application No. 17/153,128 "PET Radiopharmaceuticals for Non-invasive Evaluation of HIF-2alpha"